Atossa Genetics (NASDAQ:ATOS) Shares Cross Below 200 Day Moving Average – Should You Sell?

Atossa Genetics Inc. (NASDAQ:ATOS) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $7.49 and traded as low as $4.86. Atossa Genetics shares last traded at $4.95, with a volume of 30,295 shares traded.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. HC Wainwright boosted their target price on Atossa Genetics to $25.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Weiss Ratings lowered Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. Finally, Ascendiant Capital Markets cut their price target on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, April 10th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $36.33.

Atossa Genetics Price Performance

The company has a market capitalization of $42.62 million, a P/E ratio of -1.54 and a beta of 1.25. The stock’s 50 day moving average is $5.28 and its 200-day moving average is $7.49.

Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings data on Friday, May 8th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.12). On average, equities research analysts anticipate that Atossa Genetics Inc. will post -4.41 EPS for the current year.

Institutional Investors Weigh In On Atossa Genetics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. &PARTNERS bought a new position in Atossa Genetics in the fourth quarter worth $25,000. Hudson Bay Capital Management LP purchased a new stake in Atossa Genetics in the second quarter worth about $26,000. Gallagher Capital Advisors LLC bought a new position in shares of Atossa Genetics during the third quarter valued at approximately $27,000. JPMorgan Chase & Co. increased its stake in shares of Atossa Genetics by 1,294.2% during the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after purchasing an additional 35,474 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Atossa Genetics by 55.7% during the second quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after purchasing an additional 35,629 shares during the last quarter. 12.74% of the stock is owned by hedge funds and other institutional investors.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.